Table 6 Cost-effectiveness analyses for base case and sensitivity analyses per QALY
Cost, $ | QALYs | ICER ($/QALYs) | % Dominant | % Dominated | ≤ 3 GDP/capita | ≤ $100,000 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
PCI | MT | Δ (PCI–MT) | Δ (95% CI) | PCI | MT | Δ (PCI–MT) | Δ (95% CI) | ||||||
Overall (n = 391) | 3002 | 1740 | 1262 | (994; 1513) | 3.80 | 3.54 | 0.26 | (0.07; 0.45) | 4854 | 0 | 0 | 99 | 99 |
Overall and additional cost (n = 391) | 3131 | 1764 | 1366 | (1095; 1630) | 3.80 | 3.54 | 0.26 | (0.07; 0.45) | 5255 | 0 | 1 | 98 | 99 |
Higher cost (n = 391) | 78,063 | 45,253 | 32,811 | (25,837; 39,331) | 3.80 | 3.54 | 0.26 | (0.07; 0.45) | 126,197 | 0 | 6 | 0 | 25 |
Cost, $ | QALYs | ICER ($/QALYs) | % Dominant | % Dominated | ≤ 3 GDP/capita | ≤ $100,000 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
CABG | MT | Δ (CABG–MT) | Δ (95% CI) | CABG | MT | Δ (CABG–MT) | Δ (95% CI) | ||||||
Overall (n = 385) | 2753 | 1740 | 1013 | (761; 1235) | 3.77 | 3.54 | 0.23 | (0.03; 0.42) | 4403 | 0 | 1 | 97 | 98 |
Overall and additional cost (n = 385) | 2772 | 1764 | 1008 | (757; 1234) | 3.77 | 3.54 | 0.23 | (0.03; 0.42) | 4384 | 0 | 1 | 97 | 98 |
Higher cost (n = 385) | 71,583 | 4525 | 26,331 | (19,782; 32,111) | 3.77 | 3.54 | 0.23 | (0.03; 0.42) | 114,482 | 0 | 8 | 0 | 36 |
Cost, $ | QALYs | ICER ($/QALYs) | % Dominant | % Dominated | ≤ 3 GDP/capita | ≤ $100,00 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
PCI | CABG | Δ (PCI–CABG) | Δ (95% CI) | PCI | CABG | Δ (PCI–CABG) | Δ (95% CI) | ||||||
Overall (n = 382) | 3002 | 2753 | 249 | (64; 445) | 3.80 | 3.77 | 0.03 | (− 0.14; 0.21) | 8308 | 0 | 35 | 61 | 64 |
Overall and additional cost (n = 382) | 3130 | 2772 | 358 | (160; 565) | 3.80 | 3.77 | 0.03 | (− 0.14; 0.21) | 11,938 | 0 | 35 | 60 | 64 |
Higher cost (n = 382) | 78,064 | 71,583 | 6480 | (1672; 11,566) | 3.80 | 3.77 | 0.03 | (− 0.14; 0.21) | 216,014 | 0 | 43 | 4 | 38 |